XOMA combines extremely high gross margins with a differentiated royalty aggregation model that offers non‑dilutive capital to biotech partners. It has built a large, diversified portfolio across many disease areas and development stages, which spreads risk and provides multiple potential sources of future revenue. The company has shown it can access capital markets and structure sizeable transactions, generating meaningful revenues in certain years. Liquidity is still reasonably strong, and the operating model is capital‑light in terms of physical infrastructure, which is well‑suited to a financing‑driven business.

The main concerns are financial sustainability and execution risk. Profitability has deteriorated from solid profits to persistent, sizable losses, and both operating and free cash flow have been negative for several years. Revenues are volatile and heavily event‑driven, while fixed costs and overhead have risen, squeezing margins. The balance sheet has shifted from net cash to substantial net debt, and equity has been eroded by cumulative losses. XOMA is heavily dependent on partners’ clinical and commercial success, over timelines it cannot fully control, and may face competition from larger royalty and life‑science finance players. If cash burn continues and portfolio milestones do not arrive as hoped, the company may need further financing, potentially on less favorable terms.

Looking ahead, XOMA’s prospects hinge on two parallel tracks: portfolio performance and financial discipline. On one side, approvals, strong launches, and positive data from key partnered assets could materially lift royalties and milestone income, improving margins and cash flow over time. On the other side, the company will likely need to manage expenses, leverage, and new deal activity carefully to avoid overextending its balance sheet during a period of negative cash generation. The range of outcomes remains wide: the structural model and portfolio offer significant upside potential, but current financial trends underscore meaningful downside risk if execution or partner pipelines fall short. The story is therefore best viewed as a long‑duration, event‑driven profile rather than a steady, cash‑generative business at this stage.